4P Pharma, SATT AxLR and IBMM have concluded a co-development agreement
Montpellier, December 1st 2015
In the context of an innovative medical drug development project for the treatment of cancers, called “Imiqualines”, the oncology-pharmaco-chemical and pharmaco-toxicological team of IBMM, SATT AxLR and 4P Pharma have concluded a co-development maturation agreement with a licensing option.
4P Pharma was featured in an article in Eco121, the North region economic magazine. Lille and the North region , is a very dynamic area for biotech, and we are pleased to benefit from the collaboration of Lille Pasteur Institute and Eurasanté.